Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Free Cash Flow (2019 - 2025)

Korro Bio (KRRO) has disclosed Free Cash Flow for 6 consecutive years, with -$17.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow rose 17.26% year-over-year to -$17.4 million, compared with a TTM value of -$70.2 million through Sep 2025, up 23.48%, and an annual FY2024 reading of -$78.0 million, down 3.8% over the prior year.
  • Free Cash Flow was -$17.4 million for Q3 2025 at Korro Bio, up from -$19.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$8.9 million in Q4 2024 and bottomed at -$27.5 million in Q1 2024.
  • Average Free Cash Flow over 5 years is -$18.5 million, with a median of -$17.9 million recorded in 2021.
  • The sharpest move saw Free Cash Flow plummeted 180.92% in 2021, then surged 60.69% in 2024.
  • Year by year, Free Cash Flow stood at -$17.9 million in 2021, then grew by 9.95% to -$16.2 million in 2022, then plummeted by 40.83% to -$22.8 million in 2023, then soared by 60.69% to -$8.9 million in 2024, then crashed by 93.96% to -$17.4 million in 2025.
  • Business Quant data shows Free Cash Flow for KRRO at -$17.4 million in Q3 2025, -$19.4 million in Q2 2025, and -$24.6 million in Q1 2025.